For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total revenue | - | - | 2,569 | |
| Research and development | 3,603 | 5,806 | 319 | |
| General and administrative | 2,335 | 3,063 | 4,636 | |
| Total operating expenses | 5,938 | 8,869 | 4,955 | |
| Loss from operations | -5,938 | -8,869 | -2,386 | |
| Other income, net | - | 12,659 | 347 | |
| Non-cash interest expense on liability related to sales of future royalties and milestones | - | - | 2,867 | |
| Interest income | 411 | 377 | - | |
| Net income (loss) | -5,527 | 4,167 | -4,906 | |
| Unrealized gain on short-term investments | 20 | -15 | - | |
| Comprehensive loss | -5,507 | 4,152 | -4,906 | |
| Earnings per share, basic | -0.59 | 0.51 | -3.22 | |
| Earnings per share, diluted | -0.59 | -1 | -3.22 | |
| Weighted average number of shares outstanding, basic | 9,377,079 | 8,246,582 | 1,524,116 | |
| Weighted average number of shares outstanding, diluted | 9,377,079 | 8,455,223 | 1,524,116 | |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)